JPWO2019183226A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019183226A5 JPWO2019183226A5 JP2020545770A JP2020545770A JPWO2019183226A5 JP WO2019183226 A5 JPWO2019183226 A5 JP WO2019183226A5 JP 2020545770 A JP2020545770 A JP 2020545770A JP 2020545770 A JP2020545770 A JP 2020545770A JP WO2019183226 A5 JPWO2019183226 A5 JP WO2019183226A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- lymphoma
- aryl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 11
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrugs Drugs 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 5
- 201000003444 follicular lymphoma Diseases 0.000 claims 5
- -1 hydrate Substances 0.000 claims 5
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 4
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 4
- 206010025310 Other lymphomas Diseases 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000009721 Leukemia, Monocytic, Acute Diseases 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 210000004907 Glands Anatomy 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 claims 1
- 208000005194 Lymphoma, Large-Cell, Immunoblastic Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 210000004011 Plasma Cells Anatomy 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 125000005842 heteroatoms Chemical group 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 230000000527 lymphocytic Effects 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646314P | 2018-03-21 | 2018-03-21 | |
| US62/646,314 | 2018-03-21 | ||
| PCT/US2019/023172 WO2019183226A1 (en) | 2018-03-21 | 2019-03-20 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517116A JP2021517116A (ja) | 2021-07-15 |
| JPWO2019183226A5 true JPWO2019183226A5 (ru) | 2022-03-28 |
Family
ID=67988025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545770A Pending JP2021517116A (ja) | 2018-03-21 | 2019-03-20 | 併用療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210000838A1 (ru) |
| EP (1) | EP3768258A4 (ru) |
| JP (1) | JP2021517116A (ru) |
| KR (1) | KR20200135439A (ru) |
| CN (1) | CN112165939A (ru) |
| AU (1) | AU2019238207A1 (ru) |
| BR (1) | BR112020019082A2 (ru) |
| CA (1) | CA3093847A1 (ru) |
| EA (1) | EA202092154A1 (ru) |
| IL (1) | IL277336A (ru) |
| MA (1) | MA52090A (ru) |
| MX (1) | MX2020009773A (ru) |
| SG (1) | SG11202009137PA (ru) |
| TW (1) | TW202002983A (ru) |
| WO (1) | WO2019183226A1 (ru) |
| ZA (1) | ZA202005661B (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| CN112457403B (zh) | 2013-09-13 | 2022-11-29 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| KR20230162137A (ko) | 2016-08-16 | 2023-11-28 | 베이진 스위찰랜드 게엠베하 | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 |
| CN118252927A (zh) | 2016-08-19 | 2024-06-28 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| CN117860758A (zh) | 2017-05-23 | 2024-04-12 | 梅制药公司 | 联合疗法 |
| AU2018290532A1 (en) | 2017-06-26 | 2019-11-21 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| US11351176B2 (en) | 2017-08-14 | 2022-06-07 | Mei Pharma, Inc. | Combination therapy |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| CN113950327A (zh) * | 2019-06-10 | 2022-01-18 | 百济神州瑞士有限责任公司 | 口服胶囊剂及其制备方法 |
| US20220249491A1 (en) * | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| CN110922409A (zh) * | 2019-12-19 | 2020-03-27 | 武汉九州钰民医药科技有限公司 | 制备btk抑制剂泽布替尼的方法 |
| KR20210115375A (ko) * | 2020-03-12 | 2021-09-27 | 보령제약 주식회사 | Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI572599B (zh) * | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| WO2015083008A1 (en) * | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| US9949971B2 (en) * | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
| TW201618774A (zh) * | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法 |
-
2019
- 2019-03-20 WO PCT/US2019/023172 patent/WO2019183226A1/en unknown
- 2019-03-20 AU AU2019238207A patent/AU2019238207A1/en not_active Abandoned
- 2019-03-20 KR KR1020207030110A patent/KR20200135439A/ko not_active Application Discontinuation
- 2019-03-20 MA MA052090A patent/MA52090A/fr unknown
- 2019-03-20 EA EA202092154A patent/EA202092154A1/ru unknown
- 2019-03-20 CA CA3093847A patent/CA3093847A1/en active Pending
- 2019-03-20 EP EP19770484.4A patent/EP3768258A4/en not_active Withdrawn
- 2019-03-20 US US16/981,780 patent/US20210000838A1/en not_active Abandoned
- 2019-03-20 SG SG11202009137PA patent/SG11202009137PA/en unknown
- 2019-03-20 MX MX2020009773A patent/MX2020009773A/es unknown
- 2019-03-20 JP JP2020545770A patent/JP2021517116A/ja active Pending
- 2019-03-20 CN CN201980034008.0A patent/CN112165939A/zh active Pending
- 2019-03-20 BR BR112020019082-9A patent/BR112020019082A2/pt not_active IP Right Cessation
- 2019-03-21 TW TW108109853A patent/TW202002983A/zh unknown
-
2020
- 2020-09-11 ZA ZA2020/05661A patent/ZA202005661B/en unknown
- 2020-09-14 IL IL277336A patent/IL277336A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019183226A5 (ru) | ||
| JP2020007311A5 (ru) | ||
| JP2020531414A5 (ru) | ||
| JP2020532542A5 (ru) | ||
| JP2019529419A5 (ru) | ||
| JP2020532529A5 (ru) | ||
| JP2020517616A5 (ru) | ||
| JP2020521739A5 (ru) | ||
| RU2006131591A (ru) | Способ получения 2-аминотиазол-5-ароматических карбоксамидов в качестве ингибиторов киназ | |
| KR101982951B1 (ko) | 신규한 유형의 시티딘 유도체 및 그의 용도 | |
| JP2019535746A5 (ru) | ||
| JP2022071077A5 (ru) | ||
| JP2007521340A5 (ru) | ||
| RU2018102372A (ru) | Новые аминокислотные производные, способ их получения и фармацевтические композиции, содержащие их | |
| JP2020536971A5 (ru) | ||
| JP2014509647A5 (ru) | ||
| JP2020537645A5 (ru) | ||
| US8440675B2 (en) | Potentiator of radiation therapy | |
| RU2020109775A (ru) | Комплексная терапия | |
| JPWO2021245055A5 (ru) | ||
| JP2019534865A5 (ru) | ||
| JPWO2020023560A5 (ru) | ||
| RU2018142264A (ru) | Способ получения 5-гидроксиалкилзамещенных производных 1-фенил-1,2,4-триазола | |
| RU2656485C2 (ru) | Дейтерированные соединения хиназолинона и содержащие их фармацевтические композиции | |
| JPWO2019204490A5 (ru) |